Retrospective study of vigabatrin and psychiatric behavioural disturbances.
Vigabatrin (VGB) is an effective add-on anti-epileptic drug. The major serious adverse drug reactions (ADRs) are behavioural and psychiatric disturbances. This study does not support the view that a previous history of behavioural and psychiatric features increases the risk of behavioural/psychiatric ADRs (relative risk 1.23, 95% CI 0.57-2.66, P = 0.61). The results suggest that a low starting does of vigabatrin does not reduce the risk of psychiatric and behavioural ADRs (P = 0.31) or prevent a more overt psychotic reaction from occurring.
Wong
I C
IC
David-Lewis Centre for Epilepsy, Warford, Near Alderley Edge, Cheshire, UK.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use*; D002648:Child; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced / Q000453:epidemiology*; D008875:Middle Aged; D012189:Retrospective Studies; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000927:Anticonvulsants; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin